Dr Alberto Bossi is currently Head of the Urology and Prostate Brachytherapy Unit at the Gustave Roussy Cancer Institute in Villejuif, France. His professional career started in Italy where he was born: he graduated in Medicine and Surgery in 1988 and specialized in Radiotherapy and Diagnostic Radiology in 1992 at the University of Pavia. After a Clinical Fellowship at the Dept of Radiation Oncology at the Academic Medical Centre in Amsterdam he worked in Como and Milan. In 2001 he was appointed Adjunct Clinical Head at the Department of Radiation Oncology of the University Hospital in Leuven, Belgium where he worked till 2006 before moving to IGR.Dr Bossi is member of several scientific societies, including ESTRO, ASTRO, EAU. He has served as Coordinator of the Genito-Urinary Working Group of the EORTC in 2006. He is the Course Director of the Multidisciplinary ESTRO-EAU-ESMO Teaching Course on Prostate Cancer and teacher at both the ESO (European School of Oncology) and EAU (European Association of Urology) Prostate Courses. He is PI and co-PI (Principal Investigator) of two major European Phase III trials on Prostate Cancer and has published over 40 papers in peer-reviewed journals. Dr Bossi is reviewer for several journals including the IJROBP, European Urology, Radiotherapy and Oncology, Annals of Oncology.
Dr. Bouthaina Dabaja received her Medical Doctorate at the Lebanese University. She completed her clinical residencies at the American University of Beirut and The University of Texas MD Anderson Cancer Center. She began her career at MD Anderson following her residency in 2006 and has progressed from Assistant Professor to Professor and Section Chief of the Hematology Section in Radiation Oncology. Her primary clinical goal is patient care with an emphasis on maintaining and improving cure rate in patients with lymphoma while decreasing the short and long term side effects of treatment. She is extensively involved in clinical trials to investigate multiple strategies to deliver better treatment options for lymphoma patients with the goal of minimizing long term side effects on patients treated for mediastinal lymphomas which remains a great clinical challenge.
Associate Professor, Department of Radiation Oncology,
ESMO Board MemberDirk Arnold is Director of the Dept. Medical Oncology at Klinik für Tumorbiologie, Freiburg, Germany. Before taking this position, he was 2010 appointed as Director of the University Cancer Centre in Hamburg (UCCH) and held positions at the University Departments for Oncology and Haematology in Halle-Wittenberg and Berlin. His major field of scientific interest are gastrointestinal cancers, and here specifically modern therapeutic approaches in biomarker-driven decision processes, and multimodal treatment strategies, also including other specialities. Here, he serves as chairman of Colorectal Cancer Study Group of the German AIO, a major collaborative group in clinical oncology. Within the AIO framework, he served as founding member of the Central Clinical Trials Office, underlining his expertise also in methodology of clinical research. Furthermore, his interest is the organisation of larger collaborative research structures and of integrated cancer centre networks. Prof. Arnold is also member of the American Society of Clinical Oncology and Task Force Member of the National Cancer Institute, as well as Board member of the EORTC GI study group. Furthermore, he is board member of the German Society of Haematology and Medical Oncology (DGHO), and member of the German Cancer Society. Within ESMO, since 2012 he is section editor for GI cancers in the Guidelines Committee and Associate Editor with .
Consultant of Clinical Radiotherapy and Assistant Professor